U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager ...

Medicine

Drugs

Clinical medicine

Orphan drugs

Monoclonal antibodies

Multiple myeloma

RTT

Takeda Pharmaceutical Company

Plasma cell dyscrasias

Proteasome inhibitor

Daratumumab

Bortezomib

Johnson & Johnson

U.S. FDA

u.s. food and drug administration

janssen pharmaceutical

U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager .... View article details on HISWAI: https://pipelinereview.com/index.php/2022102681881/Antibodies/U.S.-FDA-Approves-TECVAYLI-teclistamab-cqyv-the-First-Bispecific-T-cell-Engager-Antibody-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma.html